Newton Coutinho, MD
Cardiovascular Disease · Missoula, MTNPI 1124077334
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (50.4%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Medtronic at 27.7% of the total. Reporting peaked in 2019 at $4,135 and has fallen 79.8% since, to $834 in 2025.
Across 270 payments — averaging $36.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- AstraZeneca$2K
- Pfizer$960
- Amgen$668
- Bayer$559
- Lantheus Medical Imaging, Inc.$456
- plus $2K from 22 others
What the payments were for
- Speaking & faculty fees$2,60026%
- Travel & lodging$1,69617%
- Food & beverage$4,95650%
- Education$1161%
- Other$4565%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 22 | $2,721 |
| AstraZeneca | 23 | $2,249 |
| Pfizer | 14 | $960 |
| Amgen | 42 | $668 |
| Bayer | 23 | $559 |
| Lantheus Medical Imaging, Inc. | 1 | $456 |
| GSK | 22 | $358 |
| Boehringer Ingelheim | 22 | $297 |
| Novo Nordisk | 14 | $240 |
| E.r. Squibb & Sons, L.L.C. | 10 | $202 |
| Esperion Therapeutics, Inc. | 14 | $179 |
| Johnson & Johnson | 13 | $176 |
| Regeneron Healthcare Solutions, Inc. | 12 | $109 |
| Sanofi-aventis U.S. LLC | 4 | $91 |
| Mylan Specialty L.p. | 5 | $73 |
| Novartis | 4 | $65 |
| Lundbeck LLC | 4 | $63 |
| Amarin Pharma, Inc. | 4 | $54 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $52 |
| Actelion Pharmaceuticals US, Inc. | 3 | $49 |
| Baxter Healthcare | 3 | $47 |
| Boston Scientific | 2 | $41 |
| Preventice Services, LLC | 1 | $28 |
| Merck | 2 | $23 |
| Lilly USA, LLC | 1 | $18 |
| Alnylam Pharmaceuticals Inc. | 1 | $17 |
| Abiomed | 1 | $16 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$1,900
- Reveal LINQ$1,843
- VYNDAQEL$700
- Definity$456
- AURORA EV-ICD MRI SURESCAN$251
- Kerendia$120
- ELIQUIS$111
How this compares
$9,824 in reported general payments places this provider in the 85th percentile of 49 cardiovascular disease providers in Montana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 539 | $429,969 |
| VyndaqelTafamidis Meglumine | 15 | $388,936 |
| OzempicSemaglutide | 195 | $225,183 |
| XareltoRivaroxaban | 204 | $178,452 |
| Repatha SureclickEvolocumab | 225 | $165,101 |
| EntrestoSacubitril/Valsartan | 136 | $133,757 |
| JardianceEmpagliflozin | 150 | $131,081 |
| TrulicityDulaglutide | 85 | $108,651 |
| KerendiaFinerenone | 139 | $104,650 |
| FarxigaDapagliflozin Propanediol | 98 | $101,660 |
| MounjaroTirzepatide | 73 | $90,019 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 89 | $63,417 |
| Praluent PenAlirocumab | 45 | $24,953 |
| Tresiba Flextouch U-100Insulin Degludec | 50 | $24,706 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 27 | $19,932 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Vyndaqel | $960 | $818,905554 claims |
| Novo NordiskOzempic | $240 | $225,183195 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $18 | $198,670158 claims |
| Johnson & JohnsonXarelto | $176 | $178,452204 claims |
| NovartisEntresto | $65 | $133,757136 claims |
| Boehringer IngelheimJardiance | $297 | $131,081150 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $2,249 | $121,591125 claims |
| BayerKerendia | $559 | $104,650139 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $358 | $71,298108 claims |
| Esperion Therapeutics, Inc.Nexletol | $179 | $18,62816 claims |
| MerckVerquvo, Janumet Xr | $23 | $15,59126 claims |
| AmgenCorlanor | $668 | $12,88231 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 49 cardiovascular disease providers in Montana.
Other cardiovascular disease in Missoula
- Jocelyn SpoonMissoula$17K
- Patricia KellyMissoula$12K
- Michael ReedMissoula$8K
- Gregory WoodMissoula$6K
- Morgan KelloggMissoula$4K
- Ashley MaysMissoula$4K
- Matthew WeissMissoula$3K
- Puneet BansalMissoula$2K
- Alexander JehleMissoula$2K
- Jon McGregorMissoula$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.